This special edition of Med Check features information gleaned from new research posters presented at APA’s 2012 annual meeting in Philadelphia in May. New research poster presentations are usually preliminary in nature and often involve results that have not been peer-reviewed for publication. In addition, reports may involve the use of medications ...[Read More]

On April 3, UCB announced the approval by the Food and Drug Administration (FDA) of Neupro (rotigotine transdermal system) for treatment of the signs and symptoms of advanced-stage idiopathic Parkinson’s disease (PD) and as a treatment for moderate-to-severe primary restless legs syndrome (RLS). Neupro was previously approved for early-stage idiopathic PD. ...[Read More]